How Gilgamesh Landed a $1.2B AbbVie Deal in Psychedelics
Jonathan Sporn (CEO + Founder of Gilgamesh Pharma) joins for a deep dive into next-gen psychedelic medicines, why duration matters for real-world clinical use, and more.
External link. We are not responsible for the content.
Read more βMore From PsyMed Ventures
Brain Organoids: from Space to AI with Alysson Muotri
Professor Alysson R. Muotri (geneticist and developmental biologist at UC San Diego) joins for a far out conversation...
Digital Addiction: The Investment Landscape + What Wins Now
The first thing many of us touch in the morning is a screen. Checking notifications quickly turns into a scroll, the ...
The Future of Whole Brain Emulation
Whole brain emulation without the sci-fi, by PsyMedβs Danny Carbonero
Latest News
MAPS Announces Dates for Psychedelic Science 2027; Early Bird Registrations Now Open
Denver, Colorado; May 13, 2026 βThe Multidisciplinary Association for Psychedelic Studies (MAPS) announced that early...
New psychedelic-like drugs could treat depression without making you trip
UC Davis researchers created brand-new psychedelic-like compounds by shining UV light on amino acid-based molecules. ...
Official Schedule Out Now!
Plus limited edition t-shirt announcement!
Music in Psychedelic-Assisted Therapy: An Introduction to Sound, Playlist Curation, and Why Every Practitioner Needs to Understand Both
If youβve ever sat with a client in a ketamine or psilocybin session and quietly wondered whether you chose the right...
Update on the African Psilocybin Mushroom Rivaling Cubensis
Here's what we now know about P. ochraceocentrata, formerly P. natalensis [...] Read More... The post Update on the A...
Football Player Jordan Poyer Leads the Breath of Life Tour
Football player Jordan Poyer found healing with ayahuasca and is bringing his awareness of psychedelic medicines and ...